董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vimal Kavuru | 男 | Director and Chairman of the Board | 54 | 9.62万美元 | 未持股 | 2023-08-25 |
| Prashant Kohli | 男 | Director and Chief Executive Officer | 51 | 41.55万美元 | 未持股 | 2023-08-25 |
| A. Brian Davis | 男 | Director | 56 | 未披露 | 未持股 | 2023-08-25 |
| S. George Kottayil | 男 | Director | 60 | 未披露 | 未持股 | 2023-08-25 |
| Edward Neugeboren | 男 | Director | 54 | 未披露 | 未持股 | 2023-08-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Prashant Kohli | 男 | Director and Chief Executive Officer | 51 | 41.55万美元 | 未持股 | 2023-08-25 |
| Brian Ford | 男 | Interim Chief Financial Officer | 65 | 50.51万美元 | 未持股 | 2023-08-25 |
| R. Loch Macdonald | 男 | Chief Medical Officer | 61 | 未披露 | 未持股 | 2023-08-25 |
| Carrie D'Andrea | 女 | VP Clinical Operations | 51 | 未披露 | 未持股 | 2023-08-25 |
| Amresh Kumar | 男 | VP of Program Management | 43 | 未披露 | 未持股 | 2023-08-25 |
董事简历
中英对照 | 中文 | 英文- Vimal Kavuru
-
Vimal Kavuru一直担任Cedar Pharma LLC和Aster Pharma LLC的首席执行官，瑞星于2016年12月从这两家公司收购了某些仿制药产品和相关资产。雪松和ASTER为RISING提供一定的过渡服务。Kavuru先生于2008年创立并担任Gen-Source RX的首席执行官，直到2013年，该公司是一家仿制药分销商，于2014年出售给Cardinal Health。自2007年以来，Kavuru先生一直担任Celon Labs Ltd.的董事，该公司是一家专注于肿瘤学和重症监护领域的印度专业制药公司。此外，他自2016年以来一直担任动物保健制药公司Cronus Pharma LLC的董事，是新兴专业品牌和注射剂制药公司Casper Pharma LLC的创始人，也是Grace Therapeutics，一家专注于治疗罕见和孤儿疾病的专业制药公司。Kavuru先生毕业于印度古尔巴加药学院（College of Pharmacy，Gulbarga）药学学士学位，是纽约州的注册药剂师。
Vimal Kavuru,has served as a director of the Corporation since August 2021. He has created and led several pharmaceutical companies.In addition to previously serving as the Chairman of the Grace Therapeutics Inc. ("Grace Therapeutics") board of directors, Mr. Kavuru is the Founder, Chairman and Chief Executive Officer of Rising Pharma Holdings, Inc., a U.S. generic pharmaceutical company, and Acetris Pharma Holdings, LLC, a generic pharmaceutical company serving U.S. government agencies, positions Mr. Kavuru has held since January 2013 and January 2016, respectively. Previously, Mr. Kavuru founded Citron Pharma and Lucid Pharma, each of which were sold to Aceto Corporation in 2016, Casper Pharma LLC, an emerging specialty brand pharmaceutical company, and Gen-Source RX, a national distributor of generic pharmaceuticals that was acquired by Cardinal Health in 2014. In 2007, Mr. Kavuru also co-founded Celon Labs, a specialty oncology and critical care pharmaceutical company that was acquired by Zanzibar Pharma Limited, a portfolio company of CDC Group. Mr. Kavuru was initially elected to the Board as a nominee of former shareholders of Grace Therapeutics in connection with the Corporation's acquisition of Grace Therapeutics. He is a registered pharmacist in the state of New York, holds a B.S. in Pharmacy from HKE College of Pharmacy, Bulgarga, India, and attended Long Island University, Brooklyn, New York with specialization in industrial pharmacy. - Vimal Kavuru一直担任Cedar Pharma LLC和Aster Pharma LLC的首席执行官，瑞星于2016年12月从这两家公司收购了某些仿制药产品和相关资产。雪松和ASTER为RISING提供一定的过渡服务。Kavuru先生于2008年创立并担任Gen-Source RX的首席执行官，直到2013年，该公司是一家仿制药分销商，于2014年出售给Cardinal Health。自2007年以来，Kavuru先生一直担任Celon Labs Ltd.的董事，该公司是一家专注于肿瘤学和重症监护领域的印度专业制药公司。此外，他自2016年以来一直担任动物保健制药公司Cronus Pharma LLC的董事，是新兴专业品牌和注射剂制药公司Casper Pharma LLC的创始人，也是Grace Therapeutics，一家专注于治疗罕见和孤儿疾病的专业制药公司。Kavuru先生毕业于印度古尔巴加药学院（College of Pharmacy，Gulbarga）药学学士学位，是纽约州的注册药剂师。
- Vimal Kavuru,has served as a director of the Corporation since August 2021. He has created and led several pharmaceutical companies.In addition to previously serving as the Chairman of the Grace Therapeutics Inc. ("Grace Therapeutics") board of directors, Mr. Kavuru is the Founder, Chairman and Chief Executive Officer of Rising Pharma Holdings, Inc., a U.S. generic pharmaceutical company, and Acetris Pharma Holdings, LLC, a generic pharmaceutical company serving U.S. government agencies, positions Mr. Kavuru has held since January 2013 and January 2016, respectively. Previously, Mr. Kavuru founded Citron Pharma and Lucid Pharma, each of which were sold to Aceto Corporation in 2016, Casper Pharma LLC, an emerging specialty brand pharmaceutical company, and Gen-Source RX, a national distributor of generic pharmaceuticals that was acquired by Cardinal Health in 2014. In 2007, Mr. Kavuru also co-founded Celon Labs, a specialty oncology and critical care pharmaceutical company that was acquired by Zanzibar Pharma Limited, a portfolio company of CDC Group. Mr. Kavuru was initially elected to the Board as a nominee of former shareholders of Grace Therapeutics in connection with the Corporation's acquisition of Grace Therapeutics. He is a registered pharmacist in the state of New York, holds a B.S. in Pharmacy from HKE College of Pharmacy, Bulgarga, India, and attended Long Island University, Brooklyn, New York with specialization in industrial pharmacy.
- Prashant Kohli
-
Prashant Kohli，在2021年8月加入Acasti之前，Kohli先生自2017年12月起担任Grace Therapeutics商业运营副总裁。他有专门知识，为具有独特价值主张的产品制定进入市场的计划，以满足关键的未满足的需求。他在组织设计、招聘、绩效管理、激励薪酬和损益表责任方面拥有丰富的经验，从零开始建立、部署和领导销售和市场营销。他成功地实施了基于证据的咨询销售模式，这种模式植根于对健康生态系统的深刻理解，包括患者、提供者、卫生系统、政府和付款人。他还设计了战略营销计划，以产生潜在客户和增加话语权，并通过增加覆盖面和频率的数字策略来扩大销售队伍。他拥有丰富的专业和小分子药物的商业经验，包括在罕见和孤儿疾病。Prashant曾在Archi-Tech Systems、卡地纳健康、IMS Health、Rosenbluth和邓白氏工作。他拥有奥古斯塔纳学院的计算机科学和数学学士学位，以及沃顿商学院的MBA学位。
Prashant Kohli,has served as the Corporation's Chief Executive Officer since April 2023. He has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining Acasti in August 2021, Mr. Kohli was VP, Commercial Operations of Grace Therapeutics since December 2017. He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with significant experience in organization design, recruiting, performance management, incentive compensation, and P&L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Mr. Kohli has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun & Bradstreet. He has a BA in Computer Science and Math from Augustana College and an MBA from The Wharton School. - Prashant Kohli，在2021年8月加入Acasti之前，Kohli先生自2017年12月起担任Grace Therapeutics商业运营副总裁。他有专门知识，为具有独特价值主张的产品制定进入市场的计划，以满足关键的未满足的需求。他在组织设计、招聘、绩效管理、激励薪酬和损益表责任方面拥有丰富的经验，从零开始建立、部署和领导销售和市场营销。他成功地实施了基于证据的咨询销售模式，这种模式植根于对健康生态系统的深刻理解，包括患者、提供者、卫生系统、政府和付款人。他还设计了战略营销计划，以产生潜在客户和增加话语权，并通过增加覆盖面和频率的数字策略来扩大销售队伍。他拥有丰富的专业和小分子药物的商业经验，包括在罕见和孤儿疾病。Prashant曾在Archi-Tech Systems、卡地纳健康、IMS Health、Rosenbluth和邓白氏工作。他拥有奥古斯塔纳学院的计算机科学和数学学士学位，以及沃顿商学院的MBA学位。
- Prashant Kohli,has served as the Corporation's Chief Executive Officer since April 2023. He has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining Acasti in August 2021, Mr. Kohli was VP, Commercial Operations of Grace Therapeutics since December 2017. He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with significant experience in organization design, recruiting, performance management, incentive compensation, and P&L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Mr. Kohli has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun & Bradstreet. He has a BA in Computer Science and Math from Augustana College and an MBA from The Wharton School.
- A. Brian Davis
-
A. Brian Davis，在商业和发展阶段的上市生命科学公司担任首席财务官和其他执行财务职位近三十年。Davis先生在上市公司会计和财务报告规则和条例以及财务结果评价、内部控制和业务流程方面拥有广泛的知识和背景。自2021年12月以来，戴维斯先生一直担任XyloCor Therapeutics，Inc.的首席财务官，该公司是一家临床阶段的基因治疗公司，为心血管疾病患者开发潜在疗法。戴维斯先生于2019年10月至2021年7月担任上市的NDA阶段皮肤病治疗公司Verrica Pharmaceuticals Inc.的首席财务官。在加入Verrica之前，Davis先生于2015年3月至2019年9月担任上市商业阶段生物制药公司Strongbridge生物制药公司的首席财务官。戴维斯先生以前是Tengion, Inc.的首席财务官，该公司是一家上市的再生医学公司，直到2014年12月Tengion公司申请破产，Neose技术公司是一家上市的生物制药公司。戴维斯先生拥有注册会计师执照，并在特伦顿州立学院获得会计学学士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
A. Brian Davis,has nearly three decades of experience as a Chief Financial Officer and other executive financial positions in commercial and development-stage publicly traded life science companies.Since December 2021, Mr. Davis has been the Chief Financial Officer of XyloCor Therapeutics, Inc., a clinical-stage gene therapy company developing potential therapies for patients with cardiovascular disease. Mr. Davis was the Chief Financial Officer of Verrica Pharmaceuticals Inc., a publicly traded, NDA-stage dermatology therapeutics company, from October 2019 to July 2021. Prior to joining Verrica, Mr. Davis was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Mr. Davis was previously the Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company until Tengion, Inc. filed for bankruptcy in December 2014, and Neose Technologies, Inc., a publicly traded biopharmaceutical company. Mr. Davis is licensed as a certified public accountant, and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania. - A. Brian Davis，在商业和发展阶段的上市生命科学公司担任首席财务官和其他执行财务职位近三十年。Davis先生在上市公司会计和财务报告规则和条例以及财务结果评价、内部控制和业务流程方面拥有广泛的知识和背景。自2021年12月以来，戴维斯先生一直担任XyloCor Therapeutics，Inc.的首席财务官，该公司是一家临床阶段的基因治疗公司，为心血管疾病患者开发潜在疗法。戴维斯先生于2019年10月至2021年7月担任上市的NDA阶段皮肤病治疗公司Verrica Pharmaceuticals Inc.的首席财务官。在加入Verrica之前，Davis先生于2015年3月至2019年9月担任上市商业阶段生物制药公司Strongbridge生物制药公司的首席财务官。戴维斯先生以前是Tengion, Inc.的首席财务官，该公司是一家上市的再生医学公司，直到2014年12月Tengion公司申请破产，Neose技术公司是一家上市的生物制药公司。戴维斯先生拥有注册会计师执照，并在特伦顿州立学院获得会计学学士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
- A. Brian Davis,has nearly three decades of experience as a Chief Financial Officer and other executive financial positions in commercial and development-stage publicly traded life science companies.Since December 2021, Mr. Davis has been the Chief Financial Officer of XyloCor Therapeutics, Inc., a clinical-stage gene therapy company developing potential therapies for patients with cardiovascular disease. Mr. Davis was the Chief Financial Officer of Verrica Pharmaceuticals Inc., a publicly traded, NDA-stage dermatology therapeutics company, from October 2019 to July 2021. Prior to joining Verrica, Mr. Davis was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Mr. Davis was previously the Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company until Tengion, Inc. filed for bankruptcy in December 2014, and Neose Technologies, Inc., a publicly traded biopharmaceutical company. Mr. Davis is licensed as a certified public accountant, and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania.
- S. George Kottayil
-
S. George Kottayil，在制药行业拥有超过20年的经验，在产品开发和药物输送方面具有专长。他拥有多项已获批准的专利，并且是多个美国FDA批准的药品的发明人，其中一些取得了重大成功。他与人共同创立了两家制药药物开发和药物输送技术公司，并担任公司首席执行官和董事会成员。最近，从2014年10月起，他与他人共同创立并担任Grace Therapeutics Inc.的首席执行官和董事。Grace Therapeutics Inc.是一家专注于罕见和孤儿疾病的药物递送公司，于2021年8月被Acasti制药公司收购。Kottayil博士于2021年9月至2023年5月担任公司首席运营官。Kottayil博士曾在中小型生命科学公司担任产品开发、业务运营和一般管理方面的高级职位，成功地将药物产品从实验室推进到FDA的批准和上市。他是SUBSYS 的主要发明者。SUBSYS 是一种舌下芬太尼喷雾剂，于2012年被FDA批准用于治疗突破性的癌症疼痛。SUBSYS的年销售额达到了约2亿美元的峰值，是该领域唯一一款在5分钟（SPID 5）时显示出具有统计学意义的止痛效果的产品。他在苏威制药公司的子公司Unimed Pharmaceuticals Inc.（现为艾伯维）指导业务。他在公司NDA产品的产品开发和获得FDA批准方面发挥了关键作用，其中最引人注目的是ANDROGEL 。十多年来，ANDROGEL一直是男性激素替代疗法的市场领导者，最高年收入超过10亿美元。ANDROGEL于2000年推出，重新定义了男性激素替代疗法市场，在此之前，该市场的规模远低于5000万美元，主要由ANDRODERM 贴片和深层肌肉注射服务。他在制定和执行导致受控处方药MARINOL 被美国DEA下调（CII至CIII，这在处方药行业尚属首次）的策略方面发挥了重要作用。MARINOL 被FDA批准用于癌症化疗和艾滋病相关消瘦的止吐。在FDA和DEA重新安排后，该公司实现了超过2亿美元的峰值年销售额。Kottayil博士毕业于肯塔基大学，获得有机和药物化学博士学位。
S. George Kottayil,has over two decades of experience in the pharmaceutical industry with specific expertise in product development and drug delivery. He has several approved patents to his credit and is an inventor on multiple US FDA approved drug products, a few that have achieved significant success. He co-founded two pharmaceutical drug development and drug delivery technology companies and was CEO and a member of its board of directors. Most recently, from October 2014, he co-founded and was CEO and Director of Grace Therapeutics Inc., a drug delivery company with a focus on rare and orphan disease which was acquired by Acasti Pharma Inc. in August 2021. Dr. Kottayil served as the Corporation's Chief Operating Officer from September 2021 to May 2023. Dr. Kottayil has held senior positions in product development, business operations and general management at small to medium life science companies, successfully advancing drug products from bench to FDA approval and launch. He is the principal inventor of SUBSYS – sublingual fentanyl spray that was approved by the FDA in 2012 for the treatment of breakthrough cancer pain. SUBSYS achieved peak annual sales of about US$200M and is the only product in its space that has shown statistically significant pain relief at 5 minutes (SPID 5). He directed business operations at Unimed Pharmaceuticals Inc., a division of Solvay Pharmaceuticals, now Abbvie. He played a key role in product development and obtaining FD approval for the company's NDA products most notably ANDROGEL. ANDROGEL was the market leader in male hormone replacement therapy for well over a decade with peak annual revenues exceeding US$1 billion. ANDROGEL when launched in 2000 redefined the male hormone replacement therapy market which until then was well below US$50 million and was primarily served by ANDRODERM patch and deep intra-muscular injections. He was instrumental in formulating and executing the strategy that resulted in the down-scheduling (CII to CIII – a first in the prescription drug industry) of the controlled prescription drug MARINOL by the US DEA. MARINOL was approved by the FDA for antiemesis in cancer chemotherapy and AIDS related wasting. It achieved peak annual sales of over US$200M post re-scheduling by the FDA and DEA. Dr. Kottayil graduated with a Ph.D. in Organic and Medicinal Chemistry from the University of Kentucky. - S. George Kottayil，在制药行业拥有超过20年的经验，在产品开发和药物输送方面具有专长。他拥有多项已获批准的专利，并且是多个美国FDA批准的药品的发明人，其中一些取得了重大成功。他与人共同创立了两家制药药物开发和药物输送技术公司，并担任公司首席执行官和董事会成员。最近，从2014年10月起，他与他人共同创立并担任Grace Therapeutics Inc.的首席执行官和董事。Grace Therapeutics Inc.是一家专注于罕见和孤儿疾病的药物递送公司，于2021年8月被Acasti制药公司收购。Kottayil博士于2021年9月至2023年5月担任公司首席运营官。Kottayil博士曾在中小型生命科学公司担任产品开发、业务运营和一般管理方面的高级职位，成功地将药物产品从实验室推进到FDA的批准和上市。他是SUBSYS 的主要发明者。SUBSYS 是一种舌下芬太尼喷雾剂，于2012年被FDA批准用于治疗突破性的癌症疼痛。SUBSYS的年销售额达到了约2亿美元的峰值，是该领域唯一一款在5分钟（SPID 5）时显示出具有统计学意义的止痛效果的产品。他在苏威制药公司的子公司Unimed Pharmaceuticals Inc.（现为艾伯维）指导业务。他在公司NDA产品的产品开发和获得FDA批准方面发挥了关键作用，其中最引人注目的是ANDROGEL 。十多年来，ANDROGEL一直是男性激素替代疗法的市场领导者，最高年收入超过10亿美元。ANDROGEL于2000年推出，重新定义了男性激素替代疗法市场，在此之前，该市场的规模远低于5000万美元，主要由ANDRODERM 贴片和深层肌肉注射服务。他在制定和执行导致受控处方药MARINOL 被美国DEA下调（CII至CIII，这在处方药行业尚属首次）的策略方面发挥了重要作用。MARINOL 被FDA批准用于癌症化疗和艾滋病相关消瘦的止吐。在FDA和DEA重新安排后，该公司实现了超过2亿美元的峰值年销售额。Kottayil博士毕业于肯塔基大学，获得有机和药物化学博士学位。
- S. George Kottayil,has over two decades of experience in the pharmaceutical industry with specific expertise in product development and drug delivery. He has several approved patents to his credit and is an inventor on multiple US FDA approved drug products, a few that have achieved significant success. He co-founded two pharmaceutical drug development and drug delivery technology companies and was CEO and a member of its board of directors. Most recently, from October 2014, he co-founded and was CEO and Director of Grace Therapeutics Inc., a drug delivery company with a focus on rare and orphan disease which was acquired by Acasti Pharma Inc. in August 2021. Dr. Kottayil served as the Corporation's Chief Operating Officer from September 2021 to May 2023. Dr. Kottayil has held senior positions in product development, business operations and general management at small to medium life science companies, successfully advancing drug products from bench to FDA approval and launch. He is the principal inventor of SUBSYS – sublingual fentanyl spray that was approved by the FDA in 2012 for the treatment of breakthrough cancer pain. SUBSYS achieved peak annual sales of about US$200M and is the only product in its space that has shown statistically significant pain relief at 5 minutes (SPID 5). He directed business operations at Unimed Pharmaceuticals Inc., a division of Solvay Pharmaceuticals, now Abbvie. He played a key role in product development and obtaining FD approval for the company's NDA products most notably ANDROGEL. ANDROGEL was the market leader in male hormone replacement therapy for well over a decade with peak annual revenues exceeding US$1 billion. ANDROGEL when launched in 2000 redefined the male hormone replacement therapy market which until then was well below US$50 million and was primarily served by ANDRODERM patch and deep intra-muscular injections. He was instrumental in formulating and executing the strategy that resulted in the down-scheduling (CII to CIII – a first in the prescription drug industry) of the controlled prescription drug MARINOL by the US DEA. MARINOL was approved by the FDA for antiemesis in cancer chemotherapy and AIDS related wasting. It achieved peak annual sales of over US$200M post re-scheduling by the FDA and DEA. Dr. Kottayil graduated with a Ph.D. in Organic and Medicinal Chemistry from the University of Kentucky.
- Edward Neugeboren
-
Edward Neugeboren在制药业务、商业发展、企业管理、投资银行、资产管理和机构股权研究方面拥有超过30年的医疗保健经验。自2016年1月起，Neugeboren先生担任Cronus Pharma，LLC的首席战略官，该公司是一家完全整合的研发、制造、销售和营销制药公司，Kavuru先生是该公司的负责人。Neugebroren先生领导Cronus Pharma的商业运营、战略规划和收购，还负责制定和执行整体公司战略以及公司和投资组合的收购和许可。此前，Neugeboren先生是母公司制药集团的首席战略官，该集团由仿制药公司Rising Pharma Holdings，Inc.和专业制药公司Casper Pharma，LLC组成。此外，Neugeboren先生是QuadView Healthcare Advisors的创始人和管理合伙人，该公司以前名为ArcLight Advisors，LLC，一家医疗保健投资银行和商业发展公司。Neugeboren先生以前是Ledgemont Capital Group有限责任公司的董事总经理，该公司是一家为新兴的医疗保健和技术公司提供战略和财务咨询服务的投资银行公司。Neugeboren先生还是Third Ridge Capital Management，LLC的管理合伙人，Third Ridge Capital Management，LLC是一家做多/做空美国股票的对冲基金。Neugeboren先生是Ledgemont Capital Group有限责任公司的管理成员，该公司于2013年5月申请自愿破产。Neugeboren先生拥有Finra系列24、7和63安全执照，并从联合学院获得经济学学士学位。
Edward Neugeboren,has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management and institutional equity research. Since January of 2016, Mr. Neugeboren has served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated R&D, manufacturing and sales & marketing pharmaceutical company and at which Mr. Kavuru is a principal. Mr. Neugebroren leads Cronus Pharma's commercial operations, strategic planning and acquisitions and is also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company and Casper Pharma, LLC, a specialty pharmaceutical company. Additionally, Mr. Neugeboren is Founder and Managing Partner of QuadView Healthcare Advisors, previously named ArcLight Advisors, LLC, a healthcare investment banking and business development firm. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren was a managing member of Ledgemont Capital Group, LLC when it filed for voluntary bankruptcy in May 2013. Mr. Neugeboren holds Series 24, 7 and 63 Finra security licenses and has graduated with a BA in Economics from Union College. - Edward Neugeboren在制药业务、商业发展、企业管理、投资银行、资产管理和机构股权研究方面拥有超过30年的医疗保健经验。自2016年1月起，Neugeboren先生担任Cronus Pharma，LLC的首席战略官，该公司是一家完全整合的研发、制造、销售和营销制药公司，Kavuru先生是该公司的负责人。Neugebroren先生领导Cronus Pharma的商业运营、战略规划和收购，还负责制定和执行整体公司战略以及公司和投资组合的收购和许可。此前，Neugeboren先生是母公司制药集团的首席战略官，该集团由仿制药公司Rising Pharma Holdings，Inc.和专业制药公司Casper Pharma，LLC组成。此外，Neugeboren先生是QuadView Healthcare Advisors的创始人和管理合伙人，该公司以前名为ArcLight Advisors，LLC，一家医疗保健投资银行和商业发展公司。Neugeboren先生以前是Ledgemont Capital Group有限责任公司的董事总经理，该公司是一家为新兴的医疗保健和技术公司提供战略和财务咨询服务的投资银行公司。Neugeboren先生还是Third Ridge Capital Management，LLC的管理合伙人，Third Ridge Capital Management，LLC是一家做多/做空美国股票的对冲基金。Neugeboren先生是Ledgemont Capital Group有限责任公司的管理成员，该公司于2013年5月申请自愿破产。Neugeboren先生拥有Finra系列24、7和63安全执照，并从联合学院获得经济学学士学位。
- Edward Neugeboren,has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management and institutional equity research. Since January of 2016, Mr. Neugeboren has served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated R&D, manufacturing and sales & marketing pharmaceutical company and at which Mr. Kavuru is a principal. Mr. Neugebroren leads Cronus Pharma's commercial operations, strategic planning and acquisitions and is also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company and Casper Pharma, LLC, a specialty pharmaceutical company. Additionally, Mr. Neugeboren is Founder and Managing Partner of QuadView Healthcare Advisors, previously named ArcLight Advisors, LLC, a healthcare investment banking and business development firm. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren was a managing member of Ledgemont Capital Group, LLC when it filed for voluntary bankruptcy in May 2013. Mr. Neugeboren holds Series 24, 7 and 63 Finra security licenses and has graduated with a BA in Economics from Union College.
高管简历
中英对照 | 中文 | 英文- Prashant Kohli
Prashant Kohli，在2021年8月加入Acasti之前，Kohli先生自2017年12月起担任Grace Therapeutics商业运营副总裁。他有专门知识，为具有独特价值主张的产品制定进入市场的计划，以满足关键的未满足的需求。他在组织设计、招聘、绩效管理、激励薪酬和损益表责任方面拥有丰富的经验，从零开始建立、部署和领导销售和市场营销。他成功地实施了基于证据的咨询销售模式，这种模式植根于对健康生态系统的深刻理解，包括患者、提供者、卫生系统、政府和付款人。他还设计了战略营销计划，以产生潜在客户和增加话语权，并通过增加覆盖面和频率的数字策略来扩大销售队伍。他拥有丰富的专业和小分子药物的商业经验，包括在罕见和孤儿疾病。Prashant曾在Archi-Tech Systems、卡地纳健康、IMS Health、Rosenbluth和邓白氏工作。他拥有奥古斯塔纳学院的计算机科学和数学学士学位，以及沃顿商学院的MBA学位。
Prashant Kohli,has served as the Corporation's Chief Executive Officer since April 2023. He has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining Acasti in August 2021, Mr. Kohli was VP, Commercial Operations of Grace Therapeutics since December 2017. He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with significant experience in organization design, recruiting, performance management, incentive compensation, and P&L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Mr. Kohli has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun & Bradstreet. He has a BA in Computer Science and Math from Augustana College and an MBA from The Wharton School.- Prashant Kohli，在2021年8月加入Acasti之前，Kohli先生自2017年12月起担任Grace Therapeutics商业运营副总裁。他有专门知识，为具有独特价值主张的产品制定进入市场的计划，以满足关键的未满足的需求。他在组织设计、招聘、绩效管理、激励薪酬和损益表责任方面拥有丰富的经验，从零开始建立、部署和领导销售和市场营销。他成功地实施了基于证据的咨询销售模式，这种模式植根于对健康生态系统的深刻理解，包括患者、提供者、卫生系统、政府和付款人。他还设计了战略营销计划，以产生潜在客户和增加话语权，并通过增加覆盖面和频率的数字策略来扩大销售队伍。他拥有丰富的专业和小分子药物的商业经验，包括在罕见和孤儿疾病。Prashant曾在Archi-Tech Systems、卡地纳健康、IMS Health、Rosenbluth和邓白氏工作。他拥有奥古斯塔纳学院的计算机科学和数学学士学位，以及沃顿商学院的MBA学位。
- Prashant Kohli,has served as the Corporation's Chief Executive Officer since April 2023. He has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining Acasti in August 2021, Mr. Kohli was VP, Commercial Operations of Grace Therapeutics since December 2017. He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with significant experience in organization design, recruiting, performance management, incentive compensation, and P&L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Mr. Kohli has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun & Bradstreet. He has a BA in Computer Science and Math from Augustana College and an MBA from The Wharton School.
- Brian Ford
布赖恩福特是一位出色的注册会计师，曾为上市公司和私人机构服务。福特先生一直负责制定业务复苏战略，谈判并购交易，以及管理季度和年度会计报告。最近，福特先生在安大略省的一家私人诊所担任首席财务官和高级业务顾问，包括加拿大最大的慢性疼痛管理诊所。在此之前，福特先生曾担任Telesta Therapeutics公司的首席财务官。在Telesta Therapeutics公司，福特先生帮助制定了一项新的商业计划，并积极参与所有资本交易。此前，福特创办了自己的咨询公司Petersford Consulting，为客户提供金融和商业风险服务。福特先生的职业生涯始于安永，最终成为商业风险服务公司的负责人，负责制定重要的商业计划，评估收入和成本状况，以支持预算规划，并了解增长的驱动因素，特别是医疗保健公司。此外，在安永，福特先生参与并经常带领团队完成与并购或出售业务有关的尽职调查任务，在制定财务预测、产品和市场估值以及关键会计和流程审计方面拥有丰富经验。福特先生拥有圭尔夫大学经济学、历史和英语学士学位，并拥有麦吉尔大学会计学研究生文凭。福特先生是安大略特许会计师协会会员。
Brian Ford,served as the Corporation's Chief Financial Officer from September 2020 to May 2023. Effective May 8, 2023, Mr. Ford's employment as the Corporation's Chief Financial Officer was terminated. Mr. Ford currently serves as the Corporation's Interim Chief Financial Officer under contract with the Corporation.Mr. Ford is an accomplished CPA-CA having served both publicly traded and privately owned organizations. Mr. Ford has been responsible for developing business recovery strategies, negotiating M&A transactions, as well as managing quarterly and yearly accounting reports. Prior to joining the Corporation in September 2020, most recently, Mr. Ford served as Chief Financial Officer and Senior Business Advisor at a private group of Ontario based medical clinics, including the largest chronic pain management practice in Canada from June 2017 to January 2020. Prior to that, from September 2009 to December 2016, Mr. Ford served as Chief Financial Officer at elesta Therapeutics Inc. At Telesta Therapeutics, Mr. Ford helped develop a new business plan and was heavily involved in all capital transactions. Previously, Mr. Ford started his own consulting firm, Petersford Consulting, where he provided clients with finance and business risk services. Mr. Ford began his career at Ernst & Young in 1982, eventually becoming a Principal, Business Risk Services, developing essential business plans that evaluated revenue and cost profiles supporting budget planning and understanding drivers of growth, specifically with healthcare companies. Additionally, at Ernst & Young, Mr. Ford participated in and often led teams in due diligence assignments in relation to M&A or the sale of a business, having extensive experience in developing financial forecasts, product and market valuation, and audits of critical accounting and processes. Mr. Ford holds a B.A. in Economics, History, and English from the University of Guelph and has a Graduate Diploma in Accounting from the University of McGill. Mr. Ford is a member of the Chartered Professional Accountants of Ontario (CPA Ontario).- 布赖恩福特是一位出色的注册会计师，曾为上市公司和私人机构服务。福特先生一直负责制定业务复苏战略，谈判并购交易，以及管理季度和年度会计报告。最近，福特先生在安大略省的一家私人诊所担任首席财务官和高级业务顾问，包括加拿大最大的慢性疼痛管理诊所。在此之前，福特先生曾担任Telesta Therapeutics公司的首席财务官。在Telesta Therapeutics公司，福特先生帮助制定了一项新的商业计划，并积极参与所有资本交易。此前，福特创办了自己的咨询公司Petersford Consulting，为客户提供金融和商业风险服务。福特先生的职业生涯始于安永，最终成为商业风险服务公司的负责人，负责制定重要的商业计划，评估收入和成本状况，以支持预算规划，并了解增长的驱动因素，特别是医疗保健公司。此外，在安永，福特先生参与并经常带领团队完成与并购或出售业务有关的尽职调查任务，在制定财务预测、产品和市场估值以及关键会计和流程审计方面拥有丰富经验。福特先生拥有圭尔夫大学经济学、历史和英语学士学位，并拥有麦吉尔大学会计学研究生文凭。福特先生是安大略特许会计师协会会员。
- Brian Ford,served as the Corporation's Chief Financial Officer from September 2020 to May 2023. Effective May 8, 2023, Mr. Ford's employment as the Corporation's Chief Financial Officer was terminated. Mr. Ford currently serves as the Corporation's Interim Chief Financial Officer under contract with the Corporation.Mr. Ford is an accomplished CPA-CA having served both publicly traded and privately owned organizations. Mr. Ford has been responsible for developing business recovery strategies, negotiating M&A transactions, as well as managing quarterly and yearly accounting reports. Prior to joining the Corporation in September 2020, most recently, Mr. Ford served as Chief Financial Officer and Senior Business Advisor at a private group of Ontario based medical clinics, including the largest chronic pain management practice in Canada from June 2017 to January 2020. Prior to that, from September 2009 to December 2016, Mr. Ford served as Chief Financial Officer at elesta Therapeutics Inc. At Telesta Therapeutics, Mr. Ford helped develop a new business plan and was heavily involved in all capital transactions. Previously, Mr. Ford started his own consulting firm, Petersford Consulting, where he provided clients with finance and business risk services. Mr. Ford began his career at Ernst & Young in 1982, eventually becoming a Principal, Business Risk Services, developing essential business plans that evaluated revenue and cost profiles supporting budget planning and understanding drivers of growth, specifically with healthcare companies. Additionally, at Ernst & Young, Mr. Ford participated in and often led teams in due diligence assignments in relation to M&A or the sale of a business, having extensive experience in developing financial forecasts, product and market valuation, and audits of critical accounting and processes. Mr. Ford holds a B.A. in Economics, History, and English from the University of Guelph and has a Graduate Diploma in Accounting from the University of McGill. Mr. Ford is a member of the Chartered Professional Accountants of Ontario (CPA Ontario).
- R. Loch Macdonald
R. Loch Macdonald是世界著名的神经外科医生，也是蛛网膜下腔出血领域受人尊敬的权威。麦克唐纳博士于2007年1月至2019年12月担任多伦多大学神经外科外科教授，并于2007年1月至2015年12月担任多伦多大学圣迈克尔医院神经外科主任。2018年4月至2018年8月，任亚利桑那州凤凰城巴罗神经学研究所巴罗神经外科神经外科教授；2018年12月至2019年6月，任伊利诺伊州芝加哥伊利诺伊大学医院神经外科研究员；2019年7月至2021年9月，任加利福尼亚州弗雷斯诺加州大学旧金山分校神经外科临床教授；2021年10月至今，任社区内科医生小组、社区神经科学研究所、社区区域医疗中心神经外科医生，以及社区健康合作伙伴神经科学研究医学主任。2009年，麦克唐纳博士还是Edge Therapeutics，Inc.的创始人，他在2009年至2018年期间担任该公司董事会成员，并在2011年至2018年期间担任首席学官。Macdonald博士在不列颠哥伦比亚省温哥华的不列颠哥伦比亚大学获得医学学位，并在艾伯塔省埃德蒙顿的艾伯塔大学获得实验外科博士学位。他在多伦多大学完成了神经外科住院医师的工作。
R. Loch Macdonald,has served as the Corporation's Chief Medical Officer since May 2023. Dr. Macdonald is a world-renowned practicing neurosurgeon-scientist and respected authority in subarachnoid hemorrhage. Dr. Macdonald acted as Professor, Department of Surgery, Division of Neurosurgery at the University of Toronto from January 2007 until December 2019, and was Head, Division of Neurosurgery, St. Michael's Hospital, University of Toronto from January 2007 until December 2015. He was Professor, Department of Neurological Surgery, Barrow Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, from April 2018 until August 2018; Fellow, Department of Neurosurgery, University of Illinois Hospitals in Chicago, Illinois from December 2018 until June 2019; Clinical Professor, Department of Neurological Surgery, University of California Fresno, in Fresno, California from July 2019 until September 2021; and from October 2021 to the present has been Neurosurgeon, Community Physicians Group, Community Neurosciences Institute, Community Regional Medical Center and Medical Director of Neurosciences Research, Community Health Partners. Dr. Macdonald was also a founder of Edge Therapeutics, Inc. in 2009, where he was a member of the board of directors between 2009 and 2018 and was Chief Scientific Officer between 2011 and 2018. Dr. Macdonald completed his medical degree at the University of British Columbia, Vancouver, British Columbia and his PhD in Experimental Surgery at the University of Alberta in Edmonton, Alberta. He completed his Neurosurgery residency at the University of Toronto.- R. Loch Macdonald是世界著名的神经外科医生，也是蛛网膜下腔出血领域受人尊敬的权威。麦克唐纳博士于2007年1月至2019年12月担任多伦多大学神经外科外科教授，并于2007年1月至2015年12月担任多伦多大学圣迈克尔医院神经外科主任。2018年4月至2018年8月，任亚利桑那州凤凰城巴罗神经学研究所巴罗神经外科神经外科教授；2018年12月至2019年6月，任伊利诺伊州芝加哥伊利诺伊大学医院神经外科研究员；2019年7月至2021年9月，任加利福尼亚州弗雷斯诺加州大学旧金山分校神经外科临床教授；2021年10月至今，任社区内科医生小组、社区神经科学研究所、社区区域医疗中心神经外科医生，以及社区健康合作伙伴神经科学研究医学主任。2009年，麦克唐纳博士还是Edge Therapeutics，Inc.的创始人，他在2009年至2018年期间担任该公司董事会成员，并在2011年至2018年期间担任首席学官。Macdonald博士在不列颠哥伦比亚省温哥华的不列颠哥伦比亚大学获得医学学位，并在艾伯塔省埃德蒙顿的艾伯塔大学获得实验外科博士学位。他在多伦多大学完成了神经外科住院医师的工作。
- R. Loch Macdonald,has served as the Corporation's Chief Medical Officer since May 2023. Dr. Macdonald is a world-renowned practicing neurosurgeon-scientist and respected authority in subarachnoid hemorrhage. Dr. Macdonald acted as Professor, Department of Surgery, Division of Neurosurgery at the University of Toronto from January 2007 until December 2019, and was Head, Division of Neurosurgery, St. Michael's Hospital, University of Toronto from January 2007 until December 2015. He was Professor, Department of Neurological Surgery, Barrow Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, from April 2018 until August 2018; Fellow, Department of Neurosurgery, University of Illinois Hospitals in Chicago, Illinois from December 2018 until June 2019; Clinical Professor, Department of Neurological Surgery, University of California Fresno, in Fresno, California from July 2019 until September 2021; and from October 2021 to the present has been Neurosurgeon, Community Physicians Group, Community Neurosciences Institute, Community Regional Medical Center and Medical Director of Neurosciences Research, Community Health Partners. Dr. Macdonald was also a founder of Edge Therapeutics, Inc. in 2009, where he was a member of the board of directors between 2009 and 2018 and was Chief Scientific Officer between 2011 and 2018. Dr. Macdonald completed his medical degree at the University of British Columbia, Vancouver, British Columbia and his PhD in Experimental Surgery at the University of Alberta in Edmonton, Alberta. He completed his Neurosurgery residency at the University of Toronto.
- Carrie D'Andrea
Carrie D'Andrea于2014年10月至2019年3月担任Edge Therapeutics Inc.的临床运营副总裁，并于2020年10月至2021年4月担任EryDel SpA的副总裁。D'Andrea女士于2021年7月至2022年8月在Aegle Research担任临床操作顾问，于2022年9月至2023年5月在Praxis Precisions Medicines担任临床操作顾问。D‘Andrea女士在2009年被评为医疗保健女企业家协会新星，D’Andrea女士在天普大学获得药品质量和监管事务硕士学位，并在罗格斯大学教授商业和科学硕士课程的临床试验设计和操作。
Carrie D'Andrea,has served as the Corporation's Vice President – Clinical Operations since May 2023. Ms. D'Andrea is a highly experienced professional with 25 years of experience in the pharmaceutical and biotechnology industry who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage. Ms. D'Andrea was the Vice President of Clinical Operations for Edge Therapeutics Inc. from October 2014 until March 2019 and for EryDel SpA from October 2020 until April 2021. Ms. D'Andrea was a clinical operations consultant at Aegle Research from July 2021-August 2022 and Praxis Precisions Medicines from September 2022-May 2023. Ms. D'Andrea was named a Healthcare Businesswomen's Association Rising Star in 2009 and Ms. D'Andrea received her master's degree in Pharmaceutical Quality and Regulatory Affairs from Temple University and teaches Clinical Trial Design and Operations at Rutgers University in the Master of Business and Science Program.- Carrie D'Andrea于2014年10月至2019年3月担任Edge Therapeutics Inc.的临床运营副总裁，并于2020年10月至2021年4月担任EryDel SpA的副总裁。D'Andrea女士于2021年7月至2022年8月在Aegle Research担任临床操作顾问，于2022年9月至2023年5月在Praxis Precisions Medicines担任临床操作顾问。D‘Andrea女士在2009年被评为医疗保健女企业家协会新星，D’Andrea女士在天普大学获得药品质量和监管事务硕士学位，并在罗格斯大学教授商业和科学硕士课程的临床试验设计和操作。
- Carrie D'Andrea,has served as the Corporation's Vice President – Clinical Operations since May 2023. Ms. D'Andrea is a highly experienced professional with 25 years of experience in the pharmaceutical and biotechnology industry who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage. Ms. D'Andrea was the Vice President of Clinical Operations for Edge Therapeutics Inc. from October 2014 until March 2019 and for EryDel SpA from October 2020 until April 2021. Ms. D'Andrea was a clinical operations consultant at Aegle Research from July 2021-August 2022 and Praxis Precisions Medicines from September 2022-May 2023. Ms. D'Andrea was named a Healthcare Businesswomen's Association Rising Star in 2009 and Ms. D'Andrea received her master's degree in Pharmaceutical Quality and Regulatory Affairs from Temple University and teaches Clinical Trial Design and Operations at Rutgers University in the Master of Business and Science Program.
- Amresh Kumar
Amresh Kumar曾在Grace Therapeutics Inc.（该公司于2021年8月收购）担任GTX-104的产品负责人。库马尔先生于2022年4月至2023年5月担任Foresee Pharmaceuticals Inc.项目管理高级总监，并于2015年3月至2022年1月担任Grace Therapeutics Inc.项目负责人和研发副总监。Kumar先生在印度Sunrise大学获得了药物科学博士学位，主要研究高度可溶解性肿瘤药物的复杂注射给药系统。他发表了许多研究文章，拥有10多项专利授权，并在全球范围内申请了许多专利。
Amresh Kumar,has served as the Corporation's Vice President – Program Management since May 2023. Mr. Kumar is an experienced drug development, CMC, and program management expert supporting investigational and marketed products for rare diseases and neurology. Mr. Kumar is the former product leader of GTX-104 while at Grace Therapeutics (which was acquired by the Corporation in August 2021). Mr. Kumar acted as the Sr. Director of Program Management at Foresee Pharmaceuticals Inc. from April 2022 until May 2023 and as Program Leader and Associate Director - R&D at Grace Therapeutics Inc. between March 2015 and January 2022. Mr. Kumar received a PhD in Pharmaceutical Science from Sunrise University, India, focusing on complex injectable drug delivery systems of highly soluble oncology drugs. He has published many research articles and has more than 10 granted patents and many patent applications worldwide to his credit.- Amresh Kumar曾在Grace Therapeutics Inc.（该公司于2021年8月收购）担任GTX-104的产品负责人。库马尔先生于2022年4月至2023年5月担任Foresee Pharmaceuticals Inc.项目管理高级总监，并于2015年3月至2022年1月担任Grace Therapeutics Inc.项目负责人和研发副总监。Kumar先生在印度Sunrise大学获得了药物科学博士学位，主要研究高度可溶解性肿瘤药物的复杂注射给药系统。他发表了许多研究文章，拥有10多项专利授权，并在全球范围内申请了许多专利。
- Amresh Kumar,has served as the Corporation's Vice President – Program Management since May 2023. Mr. Kumar is an experienced drug development, CMC, and program management expert supporting investigational and marketed products for rare diseases and neurology. Mr. Kumar is the former product leader of GTX-104 while at Grace Therapeutics (which was acquired by the Corporation in August 2021). Mr. Kumar acted as the Sr. Director of Program Management at Foresee Pharmaceuticals Inc. from April 2022 until May 2023 and as Program Leader and Associate Director - R&D at Grace Therapeutics Inc. between March 2015 and January 2022. Mr. Kumar received a PhD in Pharmaceutical Science from Sunrise University, India, focusing on complex injectable drug delivery systems of highly soluble oncology drugs. He has published many research articles and has more than 10 granted patents and many patent applications worldwide to his credit.